Bob Bradway, Chairman and CEO at Amgen, shared on LinkedIn:
“Amgen‘s Q2 results reflect strong performance across our business, with total revenues increasing 10% to $10.1 billion. 22 medicines delivered at least double-digit sales growth, and our six key growth drivers grew 26% year over year, generating nearly 70% of product sales.
As we continue to reach more patients, expand our existing portfolio through new indications, and advance the next generation of innovative medicines, we remain confident we can deliver growth well into the next decade.
Thank you to our colleagues and partners around the world whose commitment to patients makes this progress possible every day.
Learn more about our Q2 results.
